Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 44, 2012, Pages 18030-18035

  Olinger, Gene Garrard ^a   Pettitt, James ^a   Kim, Do ^b   Working, Cara ^c   Bohorov, Ognian ^b   Bratcher, Barry ^c   Hiatt, Ernie ^c   Hume, Steven D ^c   Johnson, Ashley K ^c   Morton, Josh ^c   Pauly, Michael ^b   Whaley, Kevin J ^b   Lear, Calli M ^a   Biggins, Julia E ^a   Scully, Corinne ^a   Hensley, Lisa ^a,d   Zeitlin, Larry ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Mapp Biopharmaceutical Inc ^*  (United States)

^c The AgriNutrition Edge   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Passive immunization; Therapy

Indexed keywords

MB 003; MONOCLONAL ANTIBODY; PALIVIZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FOLLOW UP; IMMUNOPROPHYLAXIS; NICOTIANA BENTHAMIANA; NONHUMAN; PLANT CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SURVIVAL; SYMPTOM;

EID: 84868149422     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1213709109     Document Type: Article

References (41)

1. Feldmann H, Jones S, Klenk HD, Schnittler HJ (2003) Ebola virus: From discovery to vaccine. Nat Rev Immunol 3(8):677-685.
2. Sanchez A, et al. (2001) Filoviridae Marburg and Ebola viruses. Fields Virology, eds Knipe DM, Howley PM (Lippincott Williams & Wilkins, Philadelphia), 4th Ed.
3. Warfield KL, et al. (2006) Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2(1):e1.
4. Feldmann H, et al. (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3(1):e2.
5. Geisbert TW, et al. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375(9729):1896-1905.
6. Jiang XR, et al. (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10(2):101-111.
7. Casadevall A, Scharff MD (1995) Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis 21(1):150-161.
8. Zeitlin L, Cone RA, Moench TR, Whaley KJ (2000) Preventing infectious disease with passive immunization. Microbes Infect 2(6):701-708.
9. Mupapa K, et al.; International Scientific and Technical Committee (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179(Suppl 1):S18-S23.
10. Borisevich IV, et al. (1995) Development and study of the properties of immunoglobulin against Ebola fever. Vopr Virusol, 40(6):270-273, Russian.
11. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV (1999) Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 179(Suppl 1):S218-S223.
12. Markin VAMV, Mikhaǐlov VV, Krasnianskiǐ VP, Borisevich IV, Firsova IV (1997) [Developing principles for emergency prevention and treatment of Ebola fever]. Vopr Virusol, 42(1):31-34, Russian.
13. Jahrling PBGT, et al. (1999) Evaluation of immune globulin and recombinant interferon- alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 179 (Suppl 1):S224-S234.
14. Wilson JA, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287(5458):1664-1666.
15. Parren PWHI, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76(12):6408-6412.
16. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77:195-262.
17. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW (2007) Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196(Suppl 2):S400-S403.
18. Marzi A, et al. (2012) Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7(4):e36192.
19. Oswald WB, et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3(1):e9.
20. Dye JM, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13):5034-5039.
21. Qiu X, et al. (2012) Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4(138):138ra81.
22. Ito H, Watanabe S, Takada A, Kawaoka Y (2001) Ebola virus glycoprotein: Proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75 (3):1576-1580.
23. Zeitlin L, et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 108(51): 20690-20694.
24. Giritch A, et al. (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103(40):14701- 14706.
25. Pogue GP, et al. (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 8(5):638-654.
26. Strasser R, et al. (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 6(4):392-402.
27. Bente D, Gren J, Strong JE, Feldmann H (2009) Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2(1-2):12-17.
28. Holl V, Peressin M, Moog C (2009) Antibody-mediated Fcγ receptor-based mechanisms of HIV inhibition: Recent findings and new vaccination strategies. Viruses 1(3): 1265-1294.
29. Bubnoff A (2010) Antibodies: Beyond neutralization. IAVI Rep 14(1):8-12.
30. Warfield KL, et al. (2005) Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 175(2):1184-1191.
31. Sullivan NJ, et al. (2011) CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17(9):1128-1131.
32. Koene HR, et al. (1997) FcgammaRIIIa-158V/F polymorphism influences the binding of IgG by natural k cell FcgammaRIIIa, independently of the FcgammaRIIIa-48L/R/H phenotype. Blood 90(3):1109-1114.
33. Veeramani S, et al. (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118(12):3347-3349.
34. Finstad SL, Zhang G (2010) Influence of Fc gamma-receptor polymorphisms on efficacy of antibody-mediated lymphocyte depletion in rhesus macaques. J Med Primatol, 39(4):279-280 (abstr).
35. Nguyen DC, Scinicariello F, Attanasio R (2011) Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 63(6):351-362.
36. Kuhn JH, et al. (2011) Evaluation of perceived threat differences posed by filovirus variants. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 9(4): 361-371.
37. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 93(8):3602-3607.
38. Burton DR, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266(5187):1024-1027.
39. Sullivan NJ, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424(6949):681-684.
40. Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA (1996) A rapid high-resolution highperformance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 240(2):210-226.
41. Committee On Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Pub No (NIH) 85-23